Panel Risk-Based Quality Management track
Senior Clinical Trial Leaders Discuss and Debate the Impact of ICH E6 R3, the Expected Challenges, and the Opportunities
Tue, Oct 29, 2024 · 4:32–4:57 PM CET InterContinental Barcelona
About this session
Session: RBQM IN A CHANGING REGULATORY LANDSCAPE
After much anticipation, ICH E6 R3 will be released in the fall of 2024. Companies are preparing for the updates and anticipating the impact on their organizations. In this panel, quantitative and qualitative data (gathered as part of an industry research study conducted by WCG Avoca) focused on ICH E6 R3 implementation will serve as a catalyst for discussion among senior leaders and the audience. The panel will cover the key changes being proposed and how these changes will impact clinical trial execution in terms of challenges with implementation and opportunities for success.
Speakers
-
Founder & CEO · Diligent Pharma
Moderator
-
Head of Risk Management & Centralized Monitoring · UCB Biosciences GmbH
Panelist
